Last $7.77 USD
Change Today +0.03 / 0.39%
Volume 14.9K
IMMY On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

imprimis pharmaceuticals inc (IMMY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/14 - $9.62
52 Week Low
12/30/13 - $3.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

imprimis pharmaceuticals inc (IMMY) Related Businessweek News

No Related Businessweek News Found

imprimis pharmaceuticals inc (IMMY) Details

Imprimis Pharmaceuticals, Inc. operates as a specialty pharmaceutical company focusing on the commercial development of compounded drug formulations. The company, through a strategic relationship with Professional Compounding Centers of America, Inc., expects to use its proprietary Accudel drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to facilitate its future selection, formulation, and development of potential product candidates. The company is also internally developing non-invasive, topically delivered products. Its patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. The company’s lead Phase III pain product candidate, Impracor, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. It intends to leverage the Accudel platform technology to expand and create a portfolio of topical products for various indications. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

17 Employees
Last Reported Date: 03/28/14
Founded in 1998

imprimis pharmaceuticals inc (IMMY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $296.9K
Principal Accounting & Financial Officer and ...
Total Annual Compensation: $138.8K
Compensation as of Fiscal Year 2013.

imprimis pharmaceuticals inc (IMMY) Key Developments

Imprimis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Imprimis Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenues were $441,030 against $2,500 last year. Net loss was $2,451,935 or $0.27 per share against $2,077,464 or $0.23 per share last year. During third quarter ended September 30, 2014, Imprimis used approximately $1.8 million in operating activities. For the nine months, total revenues were $1,110,141 against $7,500 last year. Net loss was $7,372,823 or $0.81 per share against $5,760,997 or $0.67 per share last year.

Imprimis Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 12, 2014

Imprimis Pharmaceuticals, Inc. announced that they will report Q3, 2014 results on Nov 12, 2014

Imprimis Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 12, 2014

Imprimis Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 12, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMY:US $7.77 USD +0.03

IMMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMY.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMMY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 63.9x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPRIMIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at